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ABSTRACT
Background Pneumatic balloon dilatation (PD) is
a regular treatment modality for achalasia. The reported
success rates of PD vary. Recurrent symptoms often
require repeated PD or surgery.
Objective To identify predicting factors for symptom
recurrence requiring repeated treatment.
Methods Between 1974 and 2006, 336 patients were
treated with PD and included in this longitudinal cohort
study. The median follow-up was 129 months (range
1e378). Recurrence of achalasia was defined as
symptom recurrence in combination with increased
lower oesophageal sphincter (LOS) pressure on
manometry, requiring repeated treatment. Patient
characteristics, results of timed barium oesophagram
and manometry as well as baseline PD characteristics
were evaluated as predictors of disease recurrence with
KaplaneMeier curves and Cox regression analysis.
Results 111 patients had symptom recurrence requiring
repeated treatment. Symptoms recurred after a mean
follow-up of 51 months (range 1e348). High recurrence
percentages were found in patients younger than
21 years in whom the 5 and 10-year risks of recurrence
were 64% and 72%, respectively. These risks were
respectively 28% and 36% in patients with classic
achalasia, respectively 48% and 60% in patients without
complete obliteration of the balloon’s waist during PD
and respectively 25% and 33% in patients with a LOS
pressure greater than 10 mm Hg at 3 months
post-dilatation. These four predictors remained
statistically significant in a multivariable Cox analysis.
Conclusion Although PD is an effective primary
treatment in patients with primary achalasia, patients are
at risk of recurrent disease, with this risk increasing
during long-term follow-up. Young age at presentation,
classic achalasia, high LOS pressure 3 months after PD
and incomplete obliteration of the balloon’s waist during
PD are the most important predicting factors for the
need for repeated treatment during follow-up. Patients
who meet one or more of these characteristics may be
considered earlier for alternative treatment, such as surgery.
Achalasia is a rare condition, with an estimated
annual incidence of one per 100 000, characterised
by a functional obstruction of the oesophagus
caused by failed relaxation of the lower oesophageal
sphincter (LOS) in combination with absent peri-
stalsis of the distal oesophagus.1 The aetiology of
achalasia is still unknown. The disease is charac-
terised by a loss of inhibitory nitrinergic neurons in
the oesophageal myenteric plexus. Proposed causes
include genetic inheritance, neuronal degeneration,
viral infection and autoimmune disease.2 The
characteristic symptoms of patients with achalasia
are dysphagia for solids and liquids, regurgitation of
undigested food or saliva, respiratory complaints
(nocturnal cough, aspiration), retrosternal pain and
weight loss. Therapeutic options aim to improve
oesophageal emptying by decreasing LOS pressure.
There are several treatment options, either endo-
scopic (botulinum toxin injection and pneumatic
balloon dilatation (PD)) or surgical.3 Most gastro-
enterologists prefer PD as first-line therapy. Never-
theless, the reported success rates of PD vary
widely, ranging in previous studies from 35% to
85% within several years of follow-up.4e11 These
marked differences may be partly explained by
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Significance of this study
What is already known about this subject?
< Several studies have reported success rates of
PD between 35% and 85%.
< The previous identified risk factors for symptom
recurrence after PD were mainly young age
(<40 years), a post-treatment LOS pressure
above 10 mm Hg and a short period of
symptoms before treatment.
< Laparoscopic myotomy combined with an
antireflux procedure provides better symptom
relief than all endoscopic and other surgical
approaches, with a low complication rate.
What are the new findings?
< After treatment with PD we found a 5-year risk
of recurrence of 28%.
< Given the long follow-up period in our study, we
were able to show that the rate of recurrence
does increase over time.
< Young age at presentation, a manometric
pattern of classic achalasia, high LOS pressure
3 months after PD, and incomplete obliteration
of the balloon’’s waist during PD are the most
important predicting factors for the need for
repeated treatment during follow-up.
How might it impact on clinical practice in the
foreseeable future?
< This implies that a stricter follow-up can be
given to patients with the above-mentioned
predicting factors, as the chance of recurrence
is significantly higher in this subgroup. Using a
stricter follow-up, recurrence (defined as symptom
recurrence in combination with objective param-
eters such as a significant increase in LOS
pressure) can be diagnosed at an earlier stage.
< Patients who meet one or more of these
characteristics may be considered earlier for
alternative treatment, such as surgery.
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differences in the length of follow-up. Recurrence of symptoms
often requires repeated PD or further treatment with surgery.
The major determinants for PD therapy failure are insufficiently
known; such knowledge would be clinically relevant as it may
aid in targeted surveillance and early intervention in high-risk
groups. Several studies have therefore tried to identify predicting
factors of clinical outcome following PD. Some did not find any
specific predictor.10 Other studies found that advanced age,
female gender, a long history of symptoms before diagnosis, high
pre-therapeutic LOS pressure, a post-dilatation LOS pressure of
less than 10 mm Hg, limited contrast retention on barium
oesophagram post-dilatation and a higher number of repeated
baseline PD dilatations were associated with a favourable
treatment outcome.5 6 8 11e15 These studies were often
performed with relatively small groups of patients. The aim of
this study was therefore to identify predicting factors for
symptom recurrence requiring repeated PD in a large cohort of
patients with primary achalasia.
PATIENTS AND METHODS
Patients
From 1974 to 2006, 433 patients (214 men and 219 women),
mean age 51.1621.6 years (range 4e92) were diagnosed with
primary achalasia in our centre. Their data were prospectively
included in a database, and they were treated and followed
according to a strict patient management, treatment and
follow-up protocol, which remained unchanged throughout the
study period.
Diagnosis
The diagnosis of achalasia was based on results from gastros-
copy, manometry and timed barium oesophagram.
Endoscopy
Upper gastrointestinal endoscopy using a fibre or video-endo-
scope (Olympus Europe, Hamburg, Germany) was performed to
rule out secondary achalasia.
Oesophageal manometry
Oesophageal manometry was performed using a low compli-
ance, pneumohydraulic water infusion system (Medical Measure
Systems, Enschede, The Netherlands) and a four-channel sili-
cone catheter (Medical Measure Systems). From May 2005
onwards we used an eight-channel water-perfused manometry
assembly with an incorporated 6 cm long reversed-perfused
sleeve sensor (Dentsleeve International Ltd, Mississauga,
Ontario, Canada). The recording sites were connected to an
eight-channel polygraph (Medical Measure Systems). The four-
channel catheter was introduced with all four recording sites in
the stomach and then manually pulled back per centimetre with
a wet swallow of 5 cc water at each centimetre. The eight-
channel catheter was introduced in the stomach and then
manually pulled back till the sleeve was positioned at the level of
the LOS. Mean resting LOS pressure was calculated as the mean
end-expiratory LOS pressure during 10 wet swallows. LOS
relaxations were considered to be absent if no change was
recorded after swallowing and complete if swallow-induced LOS
pressure returned to the basic intragastric level. A pressure fall
above basic gastric level was considered as partial relaxation.
Peristaltic wave amplitudes were also calculated as mean wave
amplitudes during 10 wet swallows. Aperistalsis was diagnosed
if all contractions after swallowing were simultaneous. We
differentiated two patterns of aperistalsis. Classic achalasia was
defined with the presence of non-transmitted or simultaneous
contractions with a low amplitude. Vigorous achalasia was
diagnosed if there were simultaneous contractions with an
amplitude of more than 37 mm Hg.
Timed barium oesophagram
Timed barium swallow was performed in the standing position
after an overnight fast. The patient was asked to drink 200 cc
barium solution (or as much as tolerated without regurgitation or
aspiration) and recordings of the oesophagus were performed at 0,
1 and 10 min after the last barium swallow. The appearance of
a so-called ‘bird’s beak’ was recorded, and the height and maximal
width of the barium column were measured at 1 and 10 min.
Pneumatic dilatation
From 1974 to 1976, homemade pneumodilators were used. Since
then, dilation balloons became commercially available, and PD
procedures were performed using a Rigiflex balloon (Boston
Scientific, Natick, Massachusetts, USA).
Baseline PD was performed on three consecutive days with
balloons of either the same or incremental (30, 35 and 40 mm)
diameter. We initially used a 40 mm balloon for all three
consecutive dilations. Under the assumption of lower perfora-
tion risk, we later adapted this protocol to a graduated approach
using balloons with incremental diameters of 30, 35 and 40 mm,
respectively, inflated like before on successive days. In the case of
recurrence, we performed a new series of dilatations on three
consecutive days, again with the same protocol as used for initial
treatment. After changing our protocol to the graduated
approach, all patients with a recurrence were treated with this
protocol, irrespective of the earlier balloon diameter protocol
used. Under conscious sedation the balloon was positioned
fluoroscopically at the gastro-oesophageal junction and inflated
to a pressure of 300 mm Hg for 1 min. Until mid-2001 patients
were hospitalised for 4e5 days, but later we switched to an
outpatient procedure.
We only performed a post-procedural oesophagram using
water-soluble contrast on suspicion of a perforation after PD.
Dilation of the oesophagus to any extent on a timed barium
oesophagram was no exclusion criterion for PD.
Post-dilatation follow-up
Following PD, all patients had a strict schedule of follow-up at 3,
12, 24 months and then every 2 years. Surveillance included
gastroscopy, manometry and timed barium oesophagram. After
8 years of follow-up surveillance included gastroscopy; further
examination was performed on indication. This schedule was
consistently followed for all patients from 1974.
Recurrence of achalasia was defined as relapse of symptoms
(in particular dysphagia, regurgitation and weight loss) in
combination with an increased LOS pressure on manometry in
comparison with the previous LOS pressure, requiring further
treatment. We did not use a specific quantified symptom
instrument to define symptom recurrence. Primary failure of
treatment was defined as the persistence or recurrence of
symptoms in the first 3 months after PD.
Evaluation of predictors of disease recurrence
Patient characteristics (age at presentation, gender), the results
of timed barium oesophagram, manometry before treatment, PD
balloon characteristics (stable vs incremental diameter and
complete vs incomplete obliteration of the balloon’s waist
during PD), as well as the results of repeated manometry
3 months post-treatment were evaluated as predictors of disease
recurrence.
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Time to recurrence was calculated from first PD.
KaplaneMeier curves were constructed to estimate the 5 and
10-year cumulative incidence of recurrence. Cox proportional
hazards regression was used to estimate univariable and multi-
variable HR. Associations between continuous predictors and
recurrence were analysed with restricted cubic spline functions
on the log hazard scale.16 These splines allow for a flexible fit of
the non-linear effects of predictors with relatively few degrees of
freedom (df). The predictive strength of each predictor in the
multivariable model was indicated by a c2 statistic, based on the
difference in e2 log likelihood of a model with and without
the predictor.17 Statistical analysis was performed using SPSS
(version 12.0), and R software (version 2.5.1).
RESULTS
Patient characteristics
From 1974 to 2006, 433 patients were diagnosed with achalasia
based on the above-mentioned criteria. Thirty-seven of them did
not undergo PD for various reasons including failure of previous
treatment elsewhere, or direct preference for cardiomyotomy.
The remaining 396 patients were treated with PD. Sixty (15.2%)
of them were excluded from analysis as they had undergone
previous endoscopic or surgical treatment elsewhere. The
remaining 336 patients were included for analysis, including 161
men and 175 women, with a mean age at initial presentation of
50 years (range 4e92). In 288 of 336 patients a manometric
subclassification of achalasia could be made. There were 222
(77%) patients with classic achalasia and 66 (23%) patients with
vigorous achalasia. The median follow-up of all patients was
129 months (range 1e378). During follow-up 94 (28%) patients
died and 74 (22%) patients were lost to follow-up. Two-hundred
and twelve patients (63%) were at baseline treated with the
fixed 40 mm balloon protocol, 63 (19%) were treated with the
incremental balloon protocol, and the remaining 61 patients
were treated with another dilatation protocol, fixed 30 mm
balloon, fixed 35 mm balloon or unknown protocol.
Complications
Among a total of 985 PD performed in 336 patients, 40 (4.1%)
procedures were associated with one or more complications. The
complications are summarised in table 1. In 13 (1.3%) of the 985
PD, an oesophageal perforation occurred. Two of these patients
required surgery; one patient underwent primary repair of the
oesophagus and one patient oesophageal resection. An oeso-
phageal stent was temporarily placed in one patient. The other
10 patients underwent conservative treatment with antibiotics
and no oral feeding. There was no mortality and all patients had
a good clinical outcome and were discharged 1767.9 days after
the perforation. Perforation occurred in five (2.4%) of the 212
patients who were repeatedly treated with a 40 mm balloon,
compared with one (1.6%) of the 63 patients who were treated
with incremental size balloons.
Six perforations occurred in patients who were treated with
a fixed dilatation protocol with a 35 mm balloon. One perfora-
tion occurred in a patient with an unknown dilatation protocol.
Perforations occurred in five of 161 (3.1%) men versus eight of
175 (4.6%) women (p <0.001). They were also more common in
patients with complete obliteration of the balloon waist
(complete vs incomplete 5.1 vs 1.8%, p<0.001). There were no
associations between perforation rates and age, LOS pressure on
manometry before PD, or duration of achalasia symptoms before
diagnosis.
Overall outcome
During follow-up, 111 of the 336 patients developed recurrence
of achalasia requiring further treatment. These first recurrences
occurred at a mean interval of 51 months (range 1e348) after
baseline treatment (figure 1). In 12 patients the symptoms
persisted or recurred within the first 3 months after PD.
Recurrences were treated with renewed PD in 88 (79%) of the
111 patients, the remainder received other treatment modalities,
in particular cardiomyotomy (9%) and botulinum toxin injec-
tion (3.6%). The 5-year risk of recurrence was 28%; the 10-year
risk of recurrence was 34% (table 2).
Forty-six of the 88 patients who had been treated with
repeated PD for disease recurrence developed a second recurrence
of achalasia at a mean interval of 70 months (range 13e372)
after renewed PD. Second recurrences were treated with
renewed PD in 34 (74%) of the 46 patients. Fifteen of those 34
patients developed a third recurrence of achalasia at a mean
interval of 109 months (range 22e242) after renewed PD and
were then treated with renewed PD in nine (60%) of the 15
patients.
Table 1 Complications related to PD
Complication
No of procedures
(n[985)
Percentage
(%)*
None 945 95.9
Post-procedural
pain
31 3.1
Fever 16 1.6
Perforation 13 1.3
Aspiration 3 0.3
Bleeding 2 0.2
*Proportions do not add up to 100% as some patients had more than one
complication, such as the combination of post-procedural pain, fever and
perforation.
PD, pneumatic balloon dilatation.
Figure 1 KaplaneMeier curve for the probability of symptom recurrence
after successful primary pneumatic balloon dilatation for achalasia.
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Predictors of outcome: univariate analysis
The risk of recurrence was significantly higher in younger
patients, those with classic achalasia, those with incomplete
obliteration of the balloon’s waist during PD and patients with
an LOS pressure greater than 10 mm Hg at 3 months after
treatment (table 2). The other factors tested, including gender
and balloon diameter used during PD, did not influence the risk
of recurrence. Furthermore, the presence or absence of oeso-
phageal dilation on a timed barium oesophagram at presentation
as well as LOS pressure before treatment did not significantly
differ between patients with or without recurrence of achalasia
during follow-up.
Table 2 shows that in 10 patients, a presumptive diagnosis of
achalasia was made despite low LOS pressures on manometry.
In view of the clinical picture with typical symptoms, a fully
compatible barium oesophagram, and a non-relaxing LOS with
stasis during endoscopy without signs of obstructing lesions, the
presumptive diagnosis of achalasia was made and patients were
treated with balloon dilation. The response to this therapy in all
10 patients with improvement of both symptoms and barium
oesophagram supported the diagnosis of achalasia and suggest
that the low LOS pressures were due to misreading in the
manometry. These patients were therefore included in our
analysis, separate analysis with the exclusion of these 10
patients did not lead to any major changes in results.
Multivariable analysis
Multivariable analysis showed that age at presentation under
50 years (with increased risk in patients with a younger age),
classic achalasia, incomplete obliteration of the balloon’s waist
during PD and LOS pressure at 3 months after treatment over
12 mm Hg were significant independent factors to predict the
development of later recurrence (all p values <0.001). No
significant interaction effects were found between these risk
factors (all p>0.05), and no simple combinations of character-
istics of high-risk patients could be found.
Relative hazard threshold in LOS pressure and age
We examined the relation between LOS pressure measured at
3 months after PD and the risk of recurrence in further detail
(figure 2). The higher the LOS pressure post-dilatation, the
greater the relative HR for recurrence. We found a threshold
value of 12 mm Hg. Above this pressure the risk of recurrence
increased more or less linearly. Younger age increased the relative
HR for recurrence (figure 3). We found a threshold value of
50 years, below which the risk of recurrence increased linearly.
DISCUSSION
Patients with achalasia are in many countries primarily treated
with PD, as this is considered to be a safe and efficient treatment
for this condition. Several studies have reported success rates for
PD of between 35% and 85%.4e11 These highly variable results
hamper the use of PD as primary treatment for achalasia.
Variation of success rates is possibly due to different periods of
follow-up with a gradual decrease in persistent success rates over
time. In a study of 72 patients with a mean follow-up of
6.5 years, the risk of recurrence after PD remained as low as
15%.10 Another study showed a persistent treatment success
rate of 60% for a patient population followed for 5e9 years post-
PD and 40% for patients followed more than 15 years post-PD.7
Table 2 Distribution of patient and treatment characteristics in relation to recurrence of achalasia
Characteristic n
Recurrence
(n)
5-Year risk of
recurrence (SE)
10-Year risk of
recurrence (SE) HR (95% CI) p Value
Sex
Male 161 52 0.2760.04 0.3360.04 1.0 0.93
Female 175 59 0.2960.04 0.3760.04 1.02 (0.7 to 1.5)
Age (years) at onset
<21 31 23 0.6460.9 0.7260.09 1.0 <0.001
21e40 91 42 0.3160.5 0.3860.06 0.4 (0.3 to 0.7)
40e50 46 11 0.1760.6 0.3360.10 0.3 (0.1 to 0.5)
>50 168 35 0.2160.3 0.2460.04 0.2 (0.1 to 0.4)
Type of achalasia
Classic 222/288 79 0.2860.03 0.3660.04 1.8 (1.0 to 3.2) 0.032
Vigorous 66/288 15 0.1860.05 0.2160.06 1.0
Timed barium oesophagram
Oesophagus dilation yes 275/326 87 0.2760.03 0.3360.03 1.0 0.36
Oesophagus dilation no 51/326 21 0.3160.07 0.3760.07 1.3 (0.8 to 2.0)
Manometry before treatment
LOS pressure #10 mm Hg 10/282 3 0.2960.18 0.2960.18 1.0 0.91
LOS pressure >10 mm Hg 272/282 88 0.2560.28 0.3260.03 0.9 (0.3 to 3.0)
Obliteration balloon’s waist
Yes 217/327 45 0.1660.03 0.1960.03 1.0 <0.001
No 110/327 62 0.4860.05 0.6060.05 3.6 (2.4 to 5.3)
Balloon diameter
Consistent (40 mm) 212 70 0.2460.03 0.3260.04 1.0 0.63
Incremental
(30e35e40 mm)
63 16 0.2760.07 0.3760.09 1.1 (0.6 to 1.9)
Other 61 25 0.3960.06 0.4260.07 1.3 (0.8 to 2.0)
Manometry 3 months after treatment
LOS pressure #10 mm Hg 82/251 15 0.1760.04 0.1960.05 1.0 0.03
LOS pressure >10 mm Hg 169/251 61 0.2560.03 0.3360.04 1.9 (1.1 to 3.3)
Total 336 111 0.2860.03 0.3460.03
HR were calculated in univariate Cox regression analysis.
LOS, lower oesophageal sphincter.
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Our results fit within the above-mentioned range of success.
However, given the long follow-up period in our study, we were
able to show that the rate of recurrence does indeed increase over
time.
Another factor that impairs the direct comparison of different
study results is the variable definition of recurrence and success.
In some studies, recurrence was defined as symptom recurrence,
sometimes based on a symptom score questionnaire such as the
Eckardt score,7 whereas other studies divided the data on the
effectiveness of treatment into four classes according to
Vantrappen and Hellemans.18 This classification is based on
symptoms of dysphagia (duration and frequency), regurgitation
and weight loss. Others defined success as the absence of the
need for further treatment.10 Against this background, we
consider our strict protocol of follow-up after PD one of the
strengths of our study. In the case of symptom recurrence we
performed a gastroscopy, a timed barium oesophagram and
a manometry. With this approach, we aimed to confirm an
increase in LOS pressures in comparison with previous
measurements, thus necessitating repeated treatment.
We deliberately used a clinical definition for persistence and
recurrence because this is most applicable and useful in the daily
management of achalasia patients. Manometry pressures, timed
swallow, or symptoms alone are insufficient tools to diagnose
recurrence and repeat PD or proceed to surgery. Our definition of
recurrence was deliberately chosen for optimal clinical manage-
ment and to prevent misdiagnoses.
Another variable factor in the literature concerning PD is the
distension protocol used. Until now there has been no strict,
uniformly accepted PD protocol for achalasia. Some investiga-
tors only perform one dilatation,8 others perform several dila-
tations with incremental diameter of the balloon, or one
dilatation at baseline and every couple of weeks after the first
dilatation re-dilatation until clinical remission is achieved.5 7 19
In a retrospective study in a group of 75 achalasia patients,
graded dilatation was found to be more effective than a single
dilatation.20 In the present study baseline PD was performed on
three consecutive days with balloons of either the same diam-
eter, or incremental (30, 35 and 40 mm) diameter. According to
the distension protocol, the majority of the patients underwent
three consecutive dilatations with a balloon diameter of 40 mm
(n¼212) or were treated with balloons with increasing diameter,
respectively, 30, 35 and eventually 40 mm (n¼63). There was no
significant difference between both groups with respect to the
risk of recurrence.
This study shows that 111 out of 336 patients treated with one
series of three PD sessions developed recurrence of achalasia
requiring further treatment. These first recurrences occurred
at a mean interval of 51 months after baseline treatment. The
5-year risk of recurrence is 28%. In one study with a variable
dilation protocol consisting of one to three initial PD sessions,
a 5e9 year success of 60%was found after treatment with PD.7 In
another study, in which the investigators performed one baseline
PD followed by on-demand strategy every 2e3 weeks till clinical
remission was achieved, a 5-year persistent success of 67% was
reported.5 These studies are in contrast to a study from German
investigators,which reported no more than 40% persistent
remission 5 years after one baseline PD.8 In comparison with
those studies, our 5-year risk of recurrence is relatively low.
After PD, all patients in the present study had a strict schedule
of follow-up at 3, 12, 24 months and then every 2 years.
Surveillance included gastroscopy, manometry and timed barium
oesophagram. After 8 years of follow-up surveillance including
gastroscopy, further examination was performed on indication.
In another study, patients were not routinely followed up after
PD, but were advised to make an appointment when symptoms
recurred.7 We believe that symptoms alone are not reliable in
assessing treatment success, but an objective assessment of
treatment and symptoms is required to achieve a higher treat-
ment success. Patients are used to having a certain level of
discomfort due to achalasia. Therefore this group of patients will
not present themselves at an early phase of recurrence of disease.
In several studies risk factors for symptom recurrence after PD
have been identified. These factors were mainly young age
(<40 years), a post-treatment LOS pressure above 10 mm Hg
and a short period of symptoms before treatment.5 6 8 12
Figure 2 Relative hazard of recurrence of achalasia and lower
oesophageal sphincter pressure (LESP) 3 months after pneumatic
balloon dilatation.The risk of recurrence increases linearly above
a threshold value of 12 mm Hg.
Figure 3 Relative hazard of recurrence of achalasia and age at diagnosis.
The risk of recurrence increases linearly below a threshold value of 50 years.
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A severely dilated oesophagus (>80 mm) has been reported to be
associated with poor outcome.4 9
We found age to be a predictive factor in treatment outcome.
Patients younger than 50 years responded less well to pneumatic
dilatation. The risk of recurrence increased linearly in patients
with an age below 50 years. High recurrence percentages were
found in patients younger than 21 years as the 5-year and
10-year risks of recurrence were 64% and 72%, respectively.
In one study achalasia was categorised into three subtypes;
type I as classic achalasia, type II as achalasia with oesophageal
compression and type III as achalasia with spastic contractions.
That study analysed treatment outcome in 83 patients and
showed each subtype to be distinct in their responsiveness to
therapy. Type IIIwas a predictor of negative treatment response.21
The current study differentiated achalasia into two subtypes,
classic achalasia (type I) and vigorous achalasia (type II). This
differentiation could be made in 288 patients. We showed that
classic achalasia was associated with a higher risk of recurrence.
In several studies treatment response was associated with low
LOS pressures post-dilatation. The most optimal response was
found in patients with a post-dilatation LOS pressure lower
than 10 mm Hg.8 11 14 The current study confirms that a low
LOS pressure post-dilation is associated with a good clinical
outcome and shows that a LOS pressure of 12 mm Hg or less at
3 months post-dilatation is associated with a significantly lower
risk of recurrence. We therefore recommend the performance
of manometry at 3 months post-dilatation to measure LOS
pressure as a predictor of treatment outcome.
Incomplete obliteration of the balloon’s waist was found to be
a significant predictor of clinical outcome as this subgroup
showed a significantly higher risk of the development of recur-
rence. In comparison with patients with complete obliteration,
patients without showed a HR of 3.6.
In the present study the presence of dilation of the oesoph-
agus was not associated with an increased risk of recurrence;
however, we only scored the parameter dilation/no dilation but
did not grade the severity of oesophageal dilation. This does not
exclude the possibility that the level of severity of dilation could
correlate with the risk of recurrence.
In a study from the USA, investigators showed that patients
with a longer duration of symptoms before diagnosis had a more
tortuous oesophageal body and tended to have an increased
oesophageal diameter observed by radiography.22 It can be
hypothesised that early detection of recurrent disease and
repeated treatment at an early stage may prevent (further)
oesophageal decompensation. Further investigation needs to be
performed to confirm this hypothesis.
There are a few shortcomings to our study. First, we did not
correlate improved emptying on a barium oesophagram inde-
pendently with symptom relief, LOS pressures and relapse rates.
Second, our pneumatic dilatations stopped at a pressure of
300 mm Hg. We did not increase the balloon pressure until
complete obliteration of the balloon waist was achieved in all
patients. Therefore our results are not the ultimate standard
that can be achieved by PD treatment. Further studies have to
show whether differentiation of the approach, for example
higher pressure, can improve results without increasing
complication rates.
Several studies have compared surgery and pneumatic dilata-
tion for the treatment of patients with achalasia.19 23e26
In one of these studies 30.3% of patients initially treated with
surgical myotomy had another intervention after 5 years and
37.5% of patients had a subsequent intervention 10 years after
initial therapy.26 In our study we obtained similar results with
PD, with a 5 and 10-year recurrence rate of 28% and 34%,
respectively.
A recently published systemic review showed that laparo-
scopic myotomy combined with an antireflux procedure
provided better symptom relief (90%) than all endoscopic and
other surgical approaches, with a low complication rate (6.3%).27
Recently, a large European prospective randomised study
compared laparoscopic Heller myotomy versus PD as baseline
treatment in 200 achalasia patients.28 One hundred and six
patients were treated with laparoscopic Heller myotomy with
Dor fundoplication and 94 patients were treated with pneu-
matic dilation. After 2 years of follow-up both treatments had
a comparable success rate of 92% versus 87%. Further follow-up
is required to evaluate long-term outcome. The long-term
outcome of this study should further determine which therapy
should be reserved for different subgroups of achalasia patients
as baseline therapy.
In summary, we conclude that PD is an effective treatment for
achalasia, but that recurrence rates after PD increase over time.
Young age at presentation, classic achalasia, incomplete obliter-
ation of the balloon’s waist during PD, and high LOS pressure at
3 months after PD are independent predicting factors of the need
for repeated PD during follow-up. These factors should be taken
into account in the follow-up strategy of achalasia patients,
leading to a stricter follow-up protocol in patients with the
above-mentioned predicting factors. Such a protocol should aim
for the timely detection of recurrence (defined as symptom
recurrence in combination with objective parameters such as
a significant increase in LOS pressure) with renewed, tailored
treatment. Our results show that most patients are then eligible
for renewed PD. However, selected cases such as those 21 years
of age or younger may in the case of recurrence be referred for
surgery earlier.
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